In an industry where time-to-market is critical, a strategic collaboration between AGC Biologics, a global leader in biopharmaceutical development, and BioConnection, an aseptic filling expert, may be the key to unlocking faster pathways from laboratory to patient. As biotechnology firms grapple
The biotechnology sector could be on the brink of a substantial change as legislative gears turn with the possibility of the BIOSECURE Act being widened to encompass drug developers. This pivot towards inclusive scrutiny, primarily targeting relationships with Chinese biopharma entities, sparks a
The rapid pace and intricate processes of modern drug development call for efficiency, precision, and scalability—goals that are increasingly being met through the adoption of laboratory automation technologies. From target identification to quality control, these systems enhance biopharma research
In a pivotal step toward enhancing cancer treatment, Oregon Therapeutics has joined forces with Lantern Pharma to escalate the development of a pivotal cancer drug, XCE853. This collaborative venture showcases AI's potential to transform medical innovations and potentially bring groundbreaking
In the evolving landscape of pharmaceuticals, the strategic partnership between Lantern Pharma and Oregon Therapeutics marks a significant milestone in the use of artificial intelligence (AI) for drug development. This collaboration centers on the advanced cancer drug candidate XCE853, an inhibitor
The inception of artificial intelligence (AI) into the realm of drug discovery heralds a new era for the pharmaceutical industry. The traditional drug development pipeline, usually protracted and costly, is undergoing a radical transformation. This article delves into the ways AI is reshaping this
